By Thomas Dobrow
J. Goldman & Company closed out its position in shares of CONMED Co. (NASDAQ:CNMD) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The hedge fund previously had a 45,654 share position in the medical technology company, valued at approximately $1,939,381. J. Goldman & Company was fully divested from the medical technology company by the time it had filed its most recent disclosure with the SEC.
Shares of CONMED Co. (NASDAQ:CNMD) opened at 42.48 on Tuesday. CONMED Co. has a 52-week low of $37.94 and a 52-week high of $60.66. The stock has a 50 day moving average of $41.74 and a 200 day moving average of $50.48. The stock has a market capitalization of $1.18 billion and a PE ratio of 34.82.
CONMED (NASDAQ:CNMD) last issued its earnings results on Wednesday, October 21st. The medical technology company reported $0.38 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.43 by $0.05. During the same period in the previous year, the business posted $0.44 earnings per share. The firm earned $169.20 million during the quarter, compared to analyst estimates of $173.96 million. The firm’s revenue for the quarter was down 3.3% compared to the same quarter last year. Analysts forecast that CONMED Co. will post $1.67 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, January 5th. Investors of record on Tuesday, December 15th will be given a dividend of $0.20 per share. The ex-dividend date is Friday, December 11th. This represents a $0.80 dividend on an annualized basis and a yield of 1.88%.
